Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.24B |
| 2 |
Microsoft
MSFT
|
+$433M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$419M |
| 4 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$332M |
| 5 |
RTX Corp
RTX
|
+$322M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AABA
Altaba Inc
AABA
|
+$267M |
| 2 |
iShares Core US Aggregate Bond ETF
AGG
|
+$181M |
| 3 |
BCR
CR Bard Inc.
BCR
|
+$134M |
| 4 |
IQVIA
IQV
|
+$134M |
| 5 |
LVLT
Level 3 Communications Inc
LVLT
|
+$121M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 7.07% |
| 2 | Financials | 5.97% |
| 3 | Healthcare | 5.8% |
| 4 | Consumer Discretionary | 5.2% |
| 5 | Communication Services | 4.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BIG
3901
CALL
DELISTED
Big Lots, Inc.
BIG
| $449K | ﹤0.01% |
8,000
-29,700
| -79% | -$1.61M |
|
3902
Antero Midstream
AM
$10.1B
| $448K | ﹤0.01% |
+22,712
| New | +$422K |
|
3903
CALL
Invesco DB Agriculture Fund
DBA
$1.23B
| $448K | ﹤0.01% |
23,900
+7,600
| +47% | +$144K |
|
3904
PUT
H&R Block
HRB
$5.86B
| $448K | ﹤0.01% |
17,100
-2,300
| -12% | -$59.7K |
|
3905
Fresenius Medical Care
FMS
$12.9B
| $447K | ﹤0.01% |
8,500
+2,536
| +43% | +$126K |
|
3906
Invesco Preferred ETF
PGX
$3.79B
| $446K | ﹤0.01% |
+30,000
| New | +$449K |
|
3907
PUT
Park Hotels & Resorts
PK
$2.97B
| $446K | ﹤0.01% |
15,510
| – | – |
|
3908
CALL
Sanmina
SANM
$10.9B
| $446K | ﹤0.01% |
13,500
+8,300
| +160% | +$290K |
|
|
CDR
3909
DELISTED
Cedar Realty Trust, Inc
CDR
| $446K | ﹤0.01% |
11,120
+2,359
| +27% | +$91.4K |
|
|
HK.WS
3910
DELISTED
Halcon Resources Corporation
HK.WS
| $446K | ﹤0.01% |
676,281
| – | – |
|
3911
CALL
Williams Companies
WMB
$86.1B
| $445K | ﹤0.01% |
14,600
-72,600
| -83% | -$2.11M |
|
|
ZAGG
3912
DELISTED
ZAGG Inc Common Stock (Delaware)
ZAGG
| $445K | ﹤0.01% |
24,023
+22,397
| +1,377% | +$419K |
|
|
SGG
3913
DELISTED
iPath Bloomberg Sugar Subindex Total Return ETN due June 24, 2038
SGG
| $445K | ﹤0.01% |
14,408
| – | – |
|
|
CEO
3914
PUT
DELISTED
CNOOC Limited
CEO
| $445K | ﹤0.01% |
3,100
-2,400
| -44% | -$325K |
|
3915
PUT
Corpay
CPAY
$25.7B
| $443K | ﹤0.01% |
2,300
| – | – |
|
|
NE
3916
PUT
DELISTED
Noble Corporation
NE
| $443K | ﹤0.01% |
97,900
+41,200
| +73% | +$171K |
|
3917
NBT Bancorp
NBTB
$2.74B
| $442K | ﹤0.01% |
12,023
+11,034
| +1,116% | +$416K |
|
3918
Stoneridge
SRI
$213M
| $442K | ﹤0.01% |
19,332
+11,947
| +162% | +$267K |
|
|
ITCI
3919
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $442K | ﹤0.01% |
30,567
-34,031
| -53% | -$525K |
|
3920
CytomX Therapeutics
CTMX
$754M
| $441K | ﹤0.01% |
20,870
-6,516
| -24% | -$135K |
|
3921
Rithm Capital
RITM
$5.69B
| $441K | ﹤0.01% |
24,676
-52,450
| -68% | -$923K |
|
|
ECYT
3922
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $441K | ﹤0.01% |
103,109
+103,078
| +332,510% | +$491K |
|
3923
CALL
Bank of Montreal
BMO
$127B
| $440K | ﹤0.01% |
5,500
-28,700
| -84% | -$2.24M |
|
3924
Federal Signal
FSS
$7.83B
| $440K | ﹤0.01% |
21,895
+9,449
| +76% | +$198K |
|
3925
The Ensign Group
ENSG
$10.7B
| $439K | ﹤0.01% |
21,145
+19,951
| +1,671% | +$428K |
|
Similar funds
Barclays's Q4 2017 Portfolio in Review
As of Q4 2017, Barclays held 7,416 positions worth $122B, up 26% from $97.1B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays deployed $19.9B of net new capital in Q4 2017, opening 435 new positions and adding to 3,853 existing holdings. Its largest new stake was iShares US Home Construction ETF: 198,606 shares worth $8.68M.
By sector, the portfolio is most concentrated in Technology at 7.1% of assets, up from 6.2% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Altaba Inc, an estimated $267M trimmed.
- Barclays's largest Q4 2017 buy was iShares US Home Construction ETF: 198,606 shares worth $8.68M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.24B increase.
- Barclays's biggest Q4 2017 reduction was Altaba Inc, cutting an estimated $267M.
- Barclays fully exited CR Bard Inc. in Q4 2017, selling an estimated $134M.
- Barclays's ten largest holdings make up 24% of its $122B portfolio in Q4 2017.
- Barclays opened 435 new positions and closed 356 in Q4 2017.
- Barclays's portfolio value rose 26% quarter-over-quarter to $122B.
Based on Barclays's 13F filing for Q4 2017, filed 14 Feb 2018.